EPITOL

Post-LOE

Teva

ANDAORALTABLET, CHEWABLE

Approved

Jul 1992

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

EPITOL by Teva is mechanism of action carbamazepine has demonstrated anticonvulsant properties in rats and mice with electrically and chemically induced seizures. Approved for the treatment of the pain associated with true trigeminal neuralgia. First approved in 1992.

Drug data last refreshed 21h ago

$0.0BPart D

Mechanism of Action

Mechanism of Action Carbamazepine has demonstrated anticonvulsant properties in rats and mice with electrically and chemically induced seizures. It appears to act by reducing polysynaptic responses and blocking the post-tetanic potentiation. Carbamazepine greatly reduces or abolishes pain induced…

Indications (1)

the treatment of the pain associated with true trigeminal neuralgia

Worked on EPITOL at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.